EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Maturity-onset diabetes of the young and related monogenic diabetes: molecular mechanisms, genotype-directed treatment, and diagnostic pathways

Kehinde Sherifdeen Sowunmi

Journal of Biochemical and Clinical Genetics · 2026

DOI: 10.24911/jbcgenetics.11-2956 ↗
AbstractBibliografische Angaben

Abstract

Background: Maturity-onset diabetes of the young (MODY) is the most common form of monogenic diabetes, with 50–90% of cases initially misclassified as type 1 or type 2 diabetes. Genetic diagnosis enables individualized treatment.

Objective: To synthesize evidence on molecular mechanisms, clinical phenotypes, diagnostic pathways, and genotype-directed treatment for MODY and related monogenic diabetes, including HNF1B-MODY and KCNJ11/ABCC8-related permanent neonatal diabetes mellitus (PNDM).

Methods: PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science were searched from inception to 30 June 2026. Eligible publications included English-language primary studies, systematic reviews, meta-analyses, and guidelines. Small case reports, non-human studies, and unavailable full texts were excluded. One reviewer conducted study selection and data extraction. Overall, 120 primary studies and 15 secondary reviews/guidelines were included. Methodological quality was assessed using the Newcastle–Ottawa Scale, Cochrane Risk of Bias tool, and AMSTAR-2. Findings were synthesized narratively.

Results: HNF1A, GCK, and HNF4A account for most MODY diagnoses in European cohorts, although frequencies vary across populations. HNF1A- and HNF4A-MODY respond to low-dose sulfonylureas, whereas GCK-MODY generally requires no pharmacotherapy. HNF1B-MODY involves multisystem disease and generally responds poorly to sulfonylureas. KCNJ11/ABCC8-related PNDM, distinct from MODY, may respond to high-dose sulfonylureas. Autoantibody status, C-peptide preservation, and family history guide genetic testing. Evidence was predominantly observational and of moderate quality, with only one randomized trial.

Conclusion: Genetic diagnosis supports precision treatment, including sulfonylurea transition, insulin avoidance, and pregnancy-specific management. Expanding genetic testing access, particularly in resource-constrained settings, and strengthening evidence across diverse populations remain priorities.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →